# Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes (HORIZON-MISS-2027-02-CANCER-03)

- Funder: European Commission – Horizon Europe (https://opengrant.co.uk/funders/european-commission-horizon-europe)
- Status: Closed
- Opens: 10 Feb 2027
- Deadline: 16 Sept 2027, 16:00 BST
- Award: €7m – €9m
- Where: International, England, Scotland, Wales, Northern Ireland
- Who can apply: Other public body, University / research org, Business (SME / sole trader), Large company
- Funding type: Grant
- Themes: Health / saving of lives, Arts / culture / heritage / science
- Source: EU Funding & Tenders – Horizon Europe (https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03)
- Last verified: 2026-11-05T12:20:20.481Z
- Canonical URL: https://opengrant.co.uk/opportunities/2c5a1d15-a292-447f-a45e-095d7d9e2fcf

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or…

How to apply: follow the funder's official guidance at https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03; OpenGrant does not take applications. The full criteria and how-to-apply notes are also on the OpenGrant page with a free account. Check the original source before applying.